CCCC
CCCC
NASDAQ · Biotechnology

C4 Therapeutics Inc

$1.82
+0.11 (+6.43%)
As of Feb 8, 2:06 PM ET ·
Analyst Consensus
Strong Buy
14
Analysts
Moderate
Coverage
Buy 13 93%
Hold 1 7%
Sell 0 0%
Price Target
Analyst Price Target +2,056.0% upside
Low Target $29.92
Average Target $39.24
High Target $50.68
Current Price $1.82
Current
$1.82
Target
$39.24
$29.92 $39.24 avg $50.68
Scenario Analysis
Bear Case
$29.92
1,544.0%
Low target
Base Case
$39.24
+2,056.0%
Avg target
Bull Case
$50.68
+2,684.6%
High target
Risk/Reward
1.7x
Balanced
Price in Context
52-Week High
$42.75
-95.7% from high
52-Week Low
$21.38
+-91.5% from low
Target vs 52W High
$39.24
-8.2% vs high
Next Earnings Report
Feb 25, 2026 · After Market Close
9d
until earnings
EPS Est: $-0.31
Earnings in 9 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 37 68% $257.58 +15.3%
AMGN
Amgen Inc
Hold 41 54% $190.87 -50.3%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +137.8%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 77% $438.34 -8.3%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.2%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -68.8%
INSM
Insmed Inc
Strong Buy 27 93% $143.40 -4.3%
BIIB
Biogen Inc
Hold 42 48% $91.45 -54.5%